Background
46,XY disorder of sex development (DSD) is characterized by incomplete gonadal development and a female or ambiguous phenotype in individuals with a normal 46,XY karyotype [
1]. The main clinical phenotypes of 46,XY DSD include bilateral undescended testes and female external genitalia, but without uterus or ovaries [
2‐
4]. The predicted morbidity among subjects with 46,XY DSD is up to 1:20,000. Among affected cases, the morbidity of hypospadias and cryptorchidism can reach 1:200 to 1:300 [
5,
6]. Many etiological factors can give rise to 46,XY DSD, with the common causes including androgen insensitivity syndrome (AIS) [
7‐
9] and steroid 5α-reductase type 2 deficiency [
10,
11]. AIS is an X-linked recessive genetic disorder that is caused by androgen receptor dysfunction [
3]. 5α-Reductase type 2 deficiency is an autosomal recessive disorder caused by decrease or loss of 5α-reductase type 2 function [
12].
5α-Reductase type 2, which is coded by the
SRD5A2 gene, is mainly expressed in epididymides, seminal vesicles, prostate, and genital skin [
13]. The function of 5α-reductase type 2 is to convert Tto DHT, which is responsible for male sexual development [
14,
15]. The loss of function of 5α-reductase type 2 leads to a failure of normal differentiation into the external genitalia, urethra, and prostate and causes 5α-reductase type 2 deficiency. To date, over 100 mutations of the
SRD5A2 gene have been identified [
16].
Recently, we identified a compound heterozygous mutation (p.H232R/p.Q6X) of the
SRD5A2 gene in two cases from a single family diagnosed with 46,XY DSD [
17]. DNA sequencing showed that the heterozygous p.H232R mutation in the
SRD5A2 gene originated from the paternal side of the family and the heterozygous p.Q6X mutation in the
SRD5A2 gene originated from the maternal side. To elucidate the effect of the p.H232R mutant on the activity of the 5α-reductase type 2 enzyme, HEK293 cells were transfected with p.H232R mutant. LC–MS showed that the mutation clearly decreased DHT production, indicating that this mutation reduced catalytic efficiency. Hence, our results confirmed compound heterozygous mutation (p.Q6X/p.H232R) as the cause of the 46,XY DSD and that p.H232R mutation decreased the catalytic efficiency of the 5α-reductase type 2 enzyme.
Discussion
In this study, we first found that two 46,XY DSD patients in a single family had a compound
SRD5A2 mutation (p.H232R/p.Q6X) [
17]. Further sequencing within this family demonstrated that the novel
SRD5A2 p.H232R mutation or the nonsense p.Q6X mutation alone would not result in the development of 46,XY DSD. LC–MS showed that the novel mutation (p.H232R) clearly decreased DHT production and
SRD5A2 catalytic efficiency.
Mutations in the
SRD5A2 gene are common genetic defects causative of 46,XY DSD, which include point mutations, deletions, and insertions [
21].
SRD5A2 functions in converting T into DHT [
22]. During early development, DHT is responsible for the formation of the male external genitalia, urethra, and prostate [
23,
24]. Some mutations in the
SRD5A2 gene cause 5α-reductase-2 deficiency syndrome [
12]. In one Thai patient with male pseudohermaphroditism, sequencing showed the compound mutation p.Q6X/p.G203S in the
SRD5A2 gene [
25]. Moreover, in one Chinese patient with hypospadias, sequencing revealed the compound mutation p.G203S/p.Q6X in the
SRD5A2 gene [
26]. In our research, the two 46,XY DSD cases had the compound heterozygous
SRD5A2 mutation p.H232R/p.Q6X. The findings showed that the heterozygous
SRD5A2 mutation (p.H232R) or the heterozygous
SRD5A2 mutation (p.Q6X) alone would not give rise to 46,XY DSD. Our and others’ researches support that the compound heterozygous
SRD5A2 mutation (p.H232R/p.Q6X) results in 46,XY DSD.
The
SRD5A2 gene, located on chromosome 2p23.1, encodes a 254-amino-acid protein and contains five exons and four introns [
24]. The p.Q6X mutation in the
SRD5A2 gene, reported only in Asians, creates a drastically truncated protein with complete loss of enzymatic activity due to the lack of both the T- and the NADPH-binding domains [
26,
27]. Histidine 232 is located in a stretch of three histidines (residues 230–232) in the
SRD5A2 enzyme. H230P mutation in the
SRD5A2 protein inactivates its enzyme activity [
28,
29]. Meanwhile, H231R mutation in the
SRD5A2 protein impairs its isozyme activity since the mutation primarily affects the ability of the enzyme to bind T [
29,
30]. Therefore, we speculate that H232R mutation in the
SRD5A2 protein could also inactivate or impair
SRD5A2 enzyme activity. Taking this previous work together with our findings, the compound heterozygous
SRD5A2 mutation p.H232R/p.Q6X could inhibit DHT formation and cause 46,XY DSD.
Most identified
SRD5A2 mutations can reduce DHT levels and cause deficiency of 5α-reductase, which is an autosomal recessive disorder [
31,
32]. The p.H232R mutation, located in exon 4 of
SRD5A2, is in the T-binding domain and most likely affects the binding of 5α-reductase 2 to T, rendering the former less active. Indeed, it was reported that p.H231R mutation in exon 4 of the
SRD5A2 gene causes 46,XY DSD via a mechanism associated with impaired binding of T [
30]. Because amino acids 230, 231 and 232 are located in exon 4 and involve the same mutation of histidine to proline or arginine, the mutational impacts are likely to be similar, both preventing binding of the enzyme to its substrate or coenzyme [
28,
29]. Our analysis of the enzymatic activity of the
SRD5A2 p.H232R mutation showed that the Vmax/Km value was lower than that of WT
SRD5A2 and reduced the
SRD5A2 catalytic efficiency, suggesting that the p.H232R mutation contributes to the development of genital ambiguity.
Conclusions
Our research strongly suggested that the compound heterozygous SRD5A2 mutation p.H232R/p.Q6X leads to 46,XY DSD and revealed the effect of the SRD5A2 p.H232R mutation on SRD5A2 catalytic efficiency. Further research is needed to construct a mouse model of 46,XY DSD with the SRD5A2 p.H232R mutation, replicate the 46,XY DSD disease phenotype, and investigate the regulatory mechanism of p.H232R on steroid 5α-reductase 2 activity in vivo.
Methods
Patients
Case 1, a 2-year-old girl with 46,XY DSD, attended our hospital. Physical examination of the female external genitalia was performed. B-ultrasound was carried out to detect male or female internal genital organs, including testis, uterus, and ovaries. In addition, hormone assay and karyotype analysis were performed, along with the sequencing of 219 DSD-related genes.
Case 2, case 1’s younger sibling, was suspected of having 46,XY DSD at 25 weeks’ gestation. Type B ultrasonic test, karyotype analysis, and SRD5A2 gene sequencing for 46,XY DSD were performed. Upon abortion of the fetus, physical examinations were performed for female external genitalia and HE staining for testis tissue and epididymis tissue.
Written informed consent for the genetic studies was obtained from the family, and all analyses were approved by the Medical Ethics Committee of the People’s Hospital of Xingtai City.
Hormone assays
Serum levels of FSH, LH, estradiol (E2), progestin (PROG), T, and prolactin (PRL) of the case 1 (III-1) were measured by radioimmunoassay.
Karyotype analysis
Peripheral blood cells from the proband were cultured in RPMI-1640 medium supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal bovine serum (FBS) for 72 h. Colchicine (20 μg/ml) was added for 2 h to arrest cells in metaphase and inhibit spindle body formation. Samples were incubated for 20 min with 75 mM potassium chloride to spread out the spindle body and fixed in Carnoy’s solution. The fixed cells were dropped onto glass slides and placed in an incubator at 75 °C for 3 h to air-dry. Giemsa solution was used to stain the G-bands of the chromosomes.
FISH analysis
The uncultured amniotic fluid cells from the aborted sibling of the case 1 (III-1) were obtained for FISH analysis. The probes were used to test chromosomes 13, 16, 18, 21, 22, X, and Y.
Genetic analysis
Peripheral blood samples of case 1, her aborted sibling, surviving sibling, father, mother, maternal uncle, grandfather, and grandmother were obtained for DNA sequencing. Genomic DNA was extracted using the TIANamp Blood DNA Kit (Tiangen), in accordance with the manufacturer’s instructions. Sequencing of 219 of the case 1 (III-1)’s DSD-related genes was performed by BGI using Illumina Genome Analyzer IIx (Supplementary Table
1). The mutated genes in case 1(III-1) and her relatives as listed above were subjected to Sanger sequencing. Mutations were identified by comparing the sequencing results of the case to the UCSC reference genome using the BWA tool.
Human SRD5A2 site-directed mutagenesis
Human SRD5A2 cDNA was kindly provided by Professor Jiahuai Han (Xiamen University) and was subcloned into vector pcDNA3.1 (with 3Flag tag, purchased from Life Technologies). To generate 695A > G mutation in the SRD5A2 gene, the pcDNA3.1-SRD5A2 plasmid was used as a template and the QuikChange II Site-Directed Mutagenesis Kit (Catalog #200,523; Agilent) was used to produce the mutation site, in accordance with the manufacturer’s instructions. The primers for cloning the 695A > G mutation in the SRD5A2 gene were as follows: SRD5A2 mF-695: gcgagcttttcaccaccGtaggttctacctcaagatgtttg, and SRD5A2 mR-695: catcttgaggtagaacctaCggtggtgaaaagctcgcag.
Transfection assay
HEK293 cells (purchased from the Chinese Academy of Sciences Cell Bank in Shanghai) were cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum (Gibco) and 1% streptomycin/penicillin (Gibco). The cells were transiently transfected with 2.0 μg of wild-type or p.H232R mutant SRD5A2 plasmids in each well of a six-well plate using TurboFect™ Transfection Reagent (Thermo Scientific), in accordance with the manufacturer’s protocol. The transfected HEK293 cells were cultured in 5% CO2 at 37 °C for 48 h before the assays.
DNA sequencing of transfection plasmids
HEK293 cells were transfected with wild-type or p.H232R mutant SRD5A2 plasmids for 48 h and Sanger sequencing was used to assess the DNA sequence. Briefly, the DNA samples were isolated by TIANamp Genomic DNA kit (Cat# DP304-02; TIANGEN, China). The concentration and purity of the DNA were determined by NanoDrop (at 260/280 nm, ND2000C; Thermo). The DNA samples were amplified by polymerase chain reaction (PCR) and sequenced by Genewiz Corporation (Suzhou, China). Primer sequences for the PCR were as follows: SRD5A2-Fseq: AGCCCGTTAAGCAGTTGAGG, and SRD5A2-Rseq: CGGCTTCTTCCGCTTCTTGA.
Quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was performed to assess the mRNA expression after transfection of the wild-type or p.H232R mutant SRD5A2 plasmid for 48 h. Total RNA was isolated by RNAiso Plus (Cat# 9109; TaKaRa) and reverse transcription was performed using the PrimeScript™ RT Reagent Kit (RR047A; Takara), in accordance with the manufacturer’s protocol. qPCR was performed using PrimeScript™ RT Reagent Kit (RR037A; Takara) with the ViiA7 Real-time PCR System (ABI). The PCR schedule was as follows: 95°C for 30 s, followed by 40 cycles of 95°C for 5 s and 60°C for 34 s. For the relative quantification of SRD5A2 mRNA, the 2−ΔΔCt method was performed. The primer sequences for qPCR were as follows: SRD5A2F: GCCACTTTGGTCGCCCTT, SRD5A2R: CTCCGTGTGCTTCCCGTAG, β-actinF: AGAGCTACGAGCTGCCTGAC, and β-actinR: AGCACTGTGTTGGCGTACAG.
Western blot
Western blot was performed as previously described [
33]. Briefly, after HEK293 cells has been transfected with wild-type or p.H232R mutant
SRD5A2 plasmids for 48 h, they were collected from six-well plates and lysed with RIPA buffer (P0013; Beyotime Biotechnology). The whole-protein lysates were separated by 12% SDS-PAGE and then transferred to nitrocellulose membranes. After blocking with 5% milk, the membranes were incubated with the primary antibodies monoclonal anti-flag (F9291; Sigma) and β-actin (sc-69879; Santa) at 4°C overnight. After rinsing with Tris-buffered saline containing 1% Tween-20 (TBST), the membrane was then incubated with appropriate HRP-conjugated secondary antibodies (sc516102; Santa Cruz) and detected with an ECL Plus kit (P1050; Applygen).
Kinetic assays
Kinetic assays were performed to assess the influence of p.H232R variant on the binding of 5α-reductase 2 enzyme to testosterone or NADPH. The HEK293 cells transfected with control vector GFP, SRD5A2 or SRD5A2 pH232R was cultured with 500 μl of fresh medium containing 500 μM NADPH (CAS: 100929–71-3, N302057; Aladdin) and various concentrations of T (0.25–8.0 μmol/L, CAS: 58–18-4, M163044; Aladdin). Or the HEK293 cells transfected with control vector GFP, SRD5A2 or SRD5A2 pH232R was cultured with 500 μl of fresh medium containing 10 μM T and various concentrations of NADPH (0.0625–2 mM/L). After incubation for 4 h, the medium was collected. The steroids were extracted with chloroform, condensed by a freeze-drying apparatus, and re-dissolved in chromatographic methanol forLC-MS analysis, using buffer A containing 1 mM formate (F112034; Aladdin) and buffer B containing 100% methanol. DHT was quantified according to the concentration and peak area of the standard DHT [CDCT-C10255010; ANPEL Laboratory Technologies (Shanghai) Inc.]. The protein concentration was determined using BCA assays (P0012S; Beyotime). The rate of enzyme production (nmol/mg protein/h) was calculated as an indicator of enzyme activity. The data were processed by Prism8 (GraphPad). The experiments on each group were repeated three times. The data are presented as mean ± SEM.
Sequence alignment of SRD5A2 in humans and other species
FASTA format SRD5A2 sequences of homologous species were downloaded from the NCBI database. Protein sequences of SRD5A2 were aligned between humans and the other homologous species using MEGA software.
Analysis of the pathogenicity of human SRD5A2 p.H232R mutation
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.